Danmark - dansk - SEGES Landbrug & Fødevarer

bayer a/s - ioxynil, bromoxynil, diflufenican - suspensionskoncentrat - 200 g/l ioxynil ; 300 g/l bromoxynil ; 50 g/l diflufenican

Danmark - dansk - SEGES Landbrug & Fødevarer

du pont danmark aps - tribenuron-methyl, tribenuron, metsulfuron-methyl, metsulfuron - vandopløseligt granulat - 222,2 g/kg tribenuron-methyl ; (~ 214 g/kg tribenuron ; 111,1 g/kg metsulfuron-methyl ; (~ 107 g/kg metsulfuron

Danmark - dansk - SEGES Landbrug & Fødevarer

nufarm deutschland gmbh - metsulfuron-methyl, metsulfuron - minigranulat - 200 g/kg metsulfuron-methyl ; (~ 193 g/kg metsulfuron)

Danmark - dansk - SEGES Landbrug & Fødevarer

du pont danmark aps - flupyrsulfuron-methyl-na, flupyrsulfuron - vanddispergerbart granulat - 500 g/kg flupyrsulfuron-methyl-na ; (~ 463 g/kg flupyrsulfuron

Danmark - dansk - SEGES Landbrug & Fødevarer

nordisk alkali ab - clethodim - emulsionskoncentrat - 240 g/l clethodim

Danmark - dansk - SEGES Landbrug & Fødevarer

basf a/s - metconazol, mepiquat-chlorid, mepiquat - vandopløseligt koncentrat - 30 g/l metconazol ; 210 g/l mepiquat-chlorid ; (~ 160 g/l mepiquat)

Danmark - dansk - SEGES Landbrug & Fødevarer

fmc agricultural solutions a/s (tidligere: cheminova a/s) - metsulfuron-methyl, metsulfuron - vandopløseligt granulat - 200 g/kg metsulfuron-methyl ; (~ 193 g/kg metsulfuron)

Danmark - dansk - SEGES Landbrug & Fødevarer

fmc agricultural solutions a/s (tidligere: cheminova a/s) - tribenuron-methyl, tribenuron, metsulfuron-methyl, metsulfuron - vandopløseligt granulat - 222,2 g/kg tribenuron-methyl ; (~ 214 g/kg tribenuron) ; 111,1 g/kg metsulfuron-methyl ; (~ 107 g/kg metsulfuron)

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig  - crisaborole - dermatitis, atopisk - andre dermatologiske præparater - staquis er indiceret til behandling af mild til moderat atopisk dermatitis hos voksne og pædiatriske patienter fra 2 år med ≤ 40% legemsoverflade (bsa), der berøres.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiske midler - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. for yderligere information om human epidermal vækstfaktor receptor 2 (her2) status henvises til afsnit 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. for yderligere oplysninger om her2-status henvises til afsnit 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.